関連する実験動画
Updated: Sep 8, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
アルツハイマー病と実験的な神経線維細胞変性における脳アルミニウム分布
まとめ
アルミニウムへの曝露は,アルツハイマー病の病理学に寄与する可能性があります. 研究によると,アルミニウムは哺乳類の神経線維細胞変性を引き起こし,これはアルツハイマー病の重要な特徴で,影響を受けた人間の脳で見つかりました.
科学分野:
- 神経科学は神経科学である.
- 病理学 パトロジー
- 毒理学 毒理学 毒理学
背景:
- 神経線維性変性症は,アルツハイマー病の特徴である.
- アルツハイマー病は,老年期および老年期前の人口に影響します.
研究 の 目的:
- 神経繊維性変性におけるアルミニウムの役割を調査する.
- 実験的なアルミニウム曝露とアルツハイマー病の病理学との関係を調査する.
主な方法:
- アルミニウムを用いた哺乳類の神経細胞における神経線維変性誘導の実験.
- アルツハイマー病患者の脳の領域におけるアルミニウム濃度の分析.
主要な成果:
- アルミニウムは,より高い哺乳類のニューロンの神経線維変性を引き起こすことが判明しました.
- アルツハイマー病患者の脳のアルミニウム濃度は,実験レベルに匹敵していました.
結論:
- 実験的証拠によると,アルミニウムは神経線維細胞の変性を引き起こす可能性があります.
- アルツハイマー病の脳におけるアルミニウム濃度の上昇は,疾患の病理に寄与する要因を示す可能性があります.
関連する概念動画
Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

